Literature DB >> 25154627

Rosacea: new and emerging treatments.

Farah A Moustafa1, Laura F Sandoval, Steven R Feldman.   

Abstract

Rosacea is a chronic inflammatory skin condition that negatively impacts patients' quality of life. We sought to review important aspects of the pathogenesis of rosacea and the role of new treatment options in its management. New, emerging treatments show promise; however, quality randomized controlled trials for many of these drugs are lacking. Brimonidine tartrate is an effective newly approved treatment for erythematotelangiectatic rosacea. Topical oxymetazoline has potential for the treatment of erythematotelangiectatic rosacea, with efficacy described in case reports and randomized controlled trials currently underway. Both oral and topical ivermectin have been studied for the treatment of papulopustular rosacea, both showing benefit; however, only topical ivermectin 1 % cream has been studied in randomized controlled trials. As our understanding of the etiology of rosacea continues to evolve, so will our options for therapeutic interventions. Further studies need to be performed to assess the long-term safety and efficacy of these treatments.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25154627     DOI: 10.1007/s40265-014-0281-x

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  43 in total

1.  Neurovascular and neuroimmune aspects in the pathophysiology of rosacea.

Authors:  Verena D Schwab; Mathias Sulk; Stephan Seeliger; Pawel Nowak; Jerome Aubert; Christian Mess; Michel Rivier; Isabelle Carlavan; Patricia Rossio; Dieter Metze; Jörg Buddenkotte; Ferda Cevikbas; Johannes J Voegel; Martin Steinhoff
Journal:  J Investig Dermatol Symp Proc       Date:  2011-12

2.  Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream.

Authors:  C Forstinger; H Kittler; M Binder
Journal:  J Am Acad Dermatol       Date:  1999-11       Impact factor: 11.527

3.  Rosacea (erythematotelangiectatic type) effectively improved by topical xylometazoline.

Authors:  Jae-Hong Kim; Yoon Seok Oh; Jae Hong Ji; Hana Bak; Sung Ku Ahn
Journal:  J Dermatol       Date:  2010-11-03       Impact factor: 4.005

4.  Ivermectin treatment of three cases of demodecidosis during human immunodeficiency virus infection.

Authors:  Emmanuel Clyti; M Nacher; D Sainte-Marie; R Pradinaud; P Couppie
Journal:  Int J Dermatol       Date:  2006-09       Impact factor: 2.736

5.  TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes.

Authors:  Kenshi Yamasaki; Kimberly Kanada; Daniel T Macleod; Andrew W Borkowski; Shin Morizane; Teruaki Nakatsuji; Anna L Cogen; Richard L Gallo
Journal:  J Invest Dermatol       Date:  2010-11-25       Impact factor: 8.551

6.  [Quality of life in patients with rosacea].

Authors:  Małgorzata Salamon; Jan Chodkiewicz; Anna Sysa-Jedrzejowska; Anna Wozniacka
Journal:  Przegl Lek       Date:  2008

7.  Density of Demodex folliculorum in rosacea: a case-control study using standardized skin-surface biopsy.

Authors:  F Forton; B Seys
Journal:  Br J Dermatol       Date:  1993-06       Impact factor: 9.302

8.  Rosacea: a study of clinical patterns, blood flow, and the role of Demodex folliculorum.

Authors:  S Sibenge; D J Gawkrodger
Journal:  J Am Acad Dermatol       Date:  1992-04       Impact factor: 11.527

9.  Mite-related bacterial antigens stimulate inflammatory cells in rosacea.

Authors:  N Lacey; S Delaney; K Kavanagh; F C Powell
Journal:  Br J Dermatol       Date:  2007-06-26       Impact factor: 9.302

10.  Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea.

Authors:  James Q Del Rosso; Guy F Webster; Mark Jackson; Marta Rendon; Phoebe Rich; Helen Torok; Mark Bradshaw
Journal:  J Am Acad Dermatol       Date:  2007-03-23       Impact factor: 11.527

View more
  5 in total

Review 1.  Interventions for rosacea.

Authors:  Esther J van Zuuren; Zbys Fedorowicz; Ben Carter; Mireille M D van der Linden; Lyn Charland
Journal:  Cochrane Database Syst Rev       Date:  2015-04-28

Review 2.  New developments in the treatment of rosacea - role of once-daily ivermectin cream.

Authors:  Leah A Cardwell; Hossein Alinia; Sara Moradi Tuchayi; Steven R Feldman
Journal:  Clin Cosmet Investig Dermatol       Date:  2016-03-18

3.  mTORC1-Mediated Angiogenesis is Required for the Development of Rosacea.

Authors:  Qinqin Peng; Ke Sha; Yingzi Liu; Mengting Chen; San Xu; Hongfu Xie; Zhili Deng; Ji Li
Journal:  Front Cell Dev Biol       Date:  2021-12-21

4.  Long-term inflammatory rosacea management with subantibiotic dose oral doxycycline 40 mg modified-release capsules once daily.

Authors:  James Q Del Rosso; Sam Brantman; Hilary Baldwin
Journal:  Dermatol Ther       Date:  2021-12-02       Impact factor: 3.858

5.  Combination of new multifunctional molecules for erythematotelangiectatic rosacea disorder.

Authors:  Hanane Chajra; Mahdi Nadim; Daniel Auriol; Kuno Schweikert; Fabrice Lefevre
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-10-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.